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This article has been retracted: please see Elsevier Policy on Article 
Withdrawal (http://www.elsevier.com/locate/withdrawalpolicy). 
This article has been retracted at the request of the Editor-in-Chief 
due to concerns regarding the legitimacy of images and data presented 
in the paper. Though a corrigendum (Can. Lett. Vol. 469, 2020, pages 
524–535) was previously published to address some of these concerns, 
this corrigendum has also been found to contain errors and therefore 
cannot stand. Specific concerns are listed below. 
The Editor and Publisher received a letter from the University of 
Portsmouth alerting us to an investigation into alleged research 
misconduct. The University concluded their investigation with external 
experts and determined that misconduct did take place in relation to the 
research involved in this paper. 
Upon our separate investigation, it has been determined that the 
paper headline relies on showing that there was considerable reduction 
of IGF1R, IL6R and EGFR post treatment in all cell lines. During review, 
it was determined that this cannot be concluded from the presented 
data. For example, in SEBTA-003 the EGFR levels go up and there is no 
difference in IGFR1. It is apparent from Fig. 4d that in the SEBTA-003 
cell line the EGFR level does not go down, which is stated in the Results 
section on page 32, it is rather going up. The data for IGFR1 are 
inconclusive and there are concerns regarding the blot. The general 
implications would be that the effects of the drug IP1867B does not seem 
to be the same for all tested cell lines, and this should have been dis-
cussed in detail by the authors. Additionally, in subsequent experiments 
(Fig. 4g and h) the SEBTA-003 cell line (no reduction of EGFR, rather 
increased expression) and the other 3 cell lines (reduction of EGFR) 
show similar responses. This is particularly evident in Fig. 4g: Two cell 
lines are compared, SEBTA-003 (increased EGFR expression) and UP- 
029 (decreased EGFR expression), both behave similarly after expo-
sure to drugs. 
The corrigendum (https://doi.org/10.1016/j.canlet.2019.10.002) 
issue is with respect to the Supplemental Figure 6i EGFR, particularly 
panel IP1867B. The Corrigendum states that the left part is a cut out of 
the very right part. If so, the bands for IP1867B should show the same 
staining pattern - but they do not. Also, in the Corrigendum, there are 
incorrect mentions between day 14 in the Figure and day 19 in the 
Figure legend. 
All authors were informed of the retraction in advance. Drs. Pritch-
ard and Duckworth agreed to the retraction. The corresponding author, 
Dr Hill, did not agree to the retraction. No response had been received 
from Drs. Mihajluk, Simms, Reay, Madureira, Howarth, Murray, Nasser 
and Pilkinton at the time of the retraction being published. 
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